{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:47:48Z","timestamp":1793047668525,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1016\/j.clinthera.2007.08.008","type":"journal-article","created":{"date-parts":[[2007,10,4]],"date-time":"2007-10-04T14:45:34Z","timestamp":1191509134000},"page":"1548-1558","source":"Crossref","is-referenced-by-count":217,"title":["A Review of the Literature on Osteonecrosis of the Jaw in Patients with Osteoporosis Treated with Oral Bisphosphonates: Prevalence, Risk Factors, and Clinical Characteristics"],"prefix":"10.1016","volume":"29","author":[{"given":"Michael","family":"Pazianas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Blumentals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajesh","family":"Kothawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"SuppI 2","key":"10.1016\/j.clinthera.2007.08.008_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ajog.2005.08.047","article-title":"Epidemiology, etiology, and diagnosis of osteoporosis","volume":"194","author":"Lane","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2007.08.008_bib2","series-title":"Rockville, Md: US Dept of Health and Human Services","article-title":"Bone health and osteoporosis: A report of the Surgeon General","year":"2004"},{"key":"10.1016\/j.clinthera.2007.08.008_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0011-5029(99)90010-X","article-title":"Management of osteoporosis","volume":"45","author":"Miller","year":"1999","journal-title":"Dis Mon"},{"key":"10.1016\/j.clinthera.2007.08.008_bib5","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1007\/s001980170015","article-title":"Impact of hip and vertebral fractures on quality-adjusted life years","volume":"12","author":"Tosteson","year":"2001","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.08.008_bib6","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archinte.164.14.1525","article-title":"National trends in osteoporosis visits and osteoporosis treatment, 1988-2003","volume":"164","author":"Stafford","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2007.08.008_bib7","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surf"},{"key":"10.1016\/j.clinthera.2007.08.008_bib8","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture Intervention TriaI","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.08.008_bib9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2007.08.008_bib10","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.clinthera.2007.08.008_bib11","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects ofrisedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.08.008_bib12","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","article-title":"Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study","volume":"54","author":"Delmas","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2007.08.008_bib13","doi-asserted-by":"crossref","first-page":"62225","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: Current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clinthera.2007.08.008_bib14","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1210\/jc.2005-0057","article-title":"Long-term safety of bisphosphonates","volume":"90","author":"Ott","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2007.08.008_bib15","first-page":"2731","article-title":"Bisphosphonates: Safety and efficacy in the treatment and prevention of osteoporosis","volume":"61","author":"Greenspan","year":"2000","journal-title":"Am Faro Physician"},{"key":"10.1016\/j.clinthera.2007.08.008_bib16","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1185\/030079906X100276","article-title":"Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis","volume":"22","author":"Iwamoto","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2007.08.008_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinthera.2007.08.008_bib18","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw-do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2007.08.008_bib19","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1359\/jbmr.060712","article-title":"Osteonecrosis of the jaw: More research needed","volume":"21","author":"Shane","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.08.008_bib20","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","article-title":"Bisphosphonates and osteonecrosis of the jaw: Cause and effect or a post hoc fallacy?","volume":"17","author":"Van den Wyngaert","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2007.08.008_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/sarh.2002.33724b","article-title":"Pathogenesis and natural history ofosteonecrosis","volume":"32","author":"Assouline-Dayan","year":"2002","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2007.08.008_bib22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/ar2050","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: The rheumatologist's role","volume":"8","author":"Capsoni","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2007.08.008_bib23","author":"Pamer"},{"key":"10.1016\/j.clinthera.2007.08.008_bib24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2007.08.008_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1345\/aph.1H521","article-title":"Bisphosphonate-induced osteonecrosis of the jaw","volume":"41","author":"Krueger","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2007.08.008_bib26","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinthera.2007.08.008_bib27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.14219\/jada.archive.2006.0350","article-title":"Osteonecrosis of the jaw and oral bisphosphonate treatment","volume":"137","author":"Nase","year":"2006","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.clinthera.2007.08.008_bib28","first-page":"36","article-title":"Bisphosphonate-related osteonecrosis of the jaws","volume":"27","author":"Yeo","year":"2005","journal-title":"Singapore Dent J"},{"key":"10.1016\/j.clinthera.2007.08.008_bib29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5694\/j.1326-5377.2005.tb06762.x","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"182","author":"Purcell","year":"2005","journal-title":"Med J Aust"},{"key":"10.1016\/j.clinthera.2007.08.008_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/01.mlg.0000187398.51857.3c","article-title":"Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonares","volume":"116","author":"Farrugia","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.clinthera.2007.08.008_bib31","first-page":"44","article-title":"Adverse oral sequelae to bisphosphonate administration","volume":"87","author":"Marunick","year":"2005","journal-title":"J Mich Dent Assoc"},{"key":"10.1016\/j.clinthera.2007.08.008_bib32","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.4065\/81.8.1100","article-title":"Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"81","author":"Kademani","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clinthera.2007.08.008_bib33","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"RE","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinthera.2007.08.008_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"issue":"SuppI 2","key":"10.1016\/j.clinthera.2007.08.008_bib35","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1111\/j.1834-7819.2005.tb00384.x","article-title":"The dental implications of bisphosphonates and bone disease","volume":"50","author":"Cheng","year":"2005","journal-title":"Aust Dent J"},{"key":"10.1016\/j.clinthera.2007.08.008_bib36","first-page":"109","article-title":"Bone necrosis of the jaws associated with bisphosphonate treatment: A report of twenty-nine cases","volume":"77","author":"Merigo","year":"2006","journal-title":"Acta Biomed"},{"key":"10.1016\/j.clinthera.2007.08.008_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.clinthera.2007.08.008_bib38","doi-asserted-by":"crossref","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: Report of a Task Force of the American Society for Bone and Mineral Research","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.08.008_bib39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S1470-2045(06)70726-4","article-title":"Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment","volume":"7","author":"Migliorati","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2007.08.008_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","article-title":"Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function","volume":"37","author":"Berenson","year":"1997","journal-title":"J Clin Pharmacol."},{"key":"10.1016\/j.clinthera.2007.08.008_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0169-409X(00)00061-2","article-title":"Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption","volume":"42","author":"Ezra","year":"2000","journal-title":"Adv Drug Deliv Rev"},{"issue":"SuppI 1","key":"10.1016\/j.clinthera.2007.08.008_bib42","first-page":"1054","article-title":"Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in post-menopausal women with osteoporosis: The HORIZON Pivotal Fracture Trial","volume":"21","author":"Black","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clinthera.2007.08.008_bib43","first-page":"801","article-title":"Bisphosphonates and osteonecrosis of the jaw","volume":"35","author":"Sambrook","year":"2006","journal-title":"Aust Faro Physician"},{"key":"10.1016\/j.clinthera.2007.08.008_bib44","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.14219\/jada.archive.2006.0355","volume":"137","author":"American Dental Association Council on Scientific Affairs","year":"2006","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.clinthera.2007.08.008_bib45","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: A potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2007.08.008_bib46","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.14219\/jada.archive.2005.0108","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper","volume":"136","author":"Migliorati","year":"2005","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.clinthera.2007.08.008_bib47","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2007.08.008_bib48","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/jama.293.20.2458","article-title":"Longer-lasting osteoporosis drugs sought","volume":"293","author":"Kuehn","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2007.08.008_bib49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2007.08.008_bib50","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.clinthera.2007.08.008_bib51","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.clinthera.2007.08.008_bib52","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807002433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291807002433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T01:24:53Z","timestamp":1587950693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291807002433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["S0149291807002433"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2007.08.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}